ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1687

Systemic Lupus Flares Based on BILAG and Sledai Rules Are Inconsistent, but May be Better Understood Using Visual Analogue Scales

Aikaterini Thanou1, Anca Askanase2, Cristina Arriens3, Teresa Aberle3, Stan Kamp3, Eliza Chakravarty3, Judith A. James4 and Joan T. Merrill3, 1Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Columbia University, College of Physicians & Surgeons, New York, NY, 3Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: SLE and outcome measures

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Evaluation of lupus flares is inconsistent using glossary-based definitions for grading (1). BILAG 2004 rates flares by new/worse organ scores. The SELENA-SLEDAI flare index (SFI) combines treatment change, new/worse features, and a weighted physician’s global assessment (SFI-PGA) visual analogue scale (VAS). A modified SFI (mSFI) improves accuracy by excluding medication criteria while clinicians differentiate mild from moderate flare (2). The Rapid Evaluation of Activity in Lupus (LFA-REALTM) expands the SFI-PGA and other earlier systems (3) for comprehensive VAS-based evaluation of individual symptoms, organs, or global disease. We compared mSFI and BILAG flares during a clinical trial, using SFI-PGA and LFA-REALTM to clarify their differences.

Methods: Disease activity (SLEDAI, BILAG 2004, mSFI, SFI-PGA, and LFA-REALTM) was rated monthly in a clinical trial. Severity of mSFI and BILAG flares was compared to SFI-PGA and LFA-REALTM changes by receiver operating characteristic (ROC) curve analysis.

Results: 50 SLE patients were examined at 430 monthly visit pairs. The mSFI defined 108 flares (73 mild, 34 moderate, 1 severe); BILAG only 77 (63 mild, 8 moderate, 6 severe) (Table 1). The mSFI rated 36 mild BILAG flares as mild and 26 as moderate. These were effectively discriminated by SFI-PGA or LFA-REALTM (p<0.001). There were 34 moderate mSFI flares vs only 8 by BILAG (new/worse B in ≥2 organ domains). Also, mSFI flare was scored in 32 of 353 visit pairs with no BILAG flare (27 with mild flare in <3 BILAG domains). Both SFI-PGA and LFA-REALTM captured flares by mSFI or BILAG (ROC analysis, p<0.0001 for all). Mild vs moderate/severe mSFI flares were distinguished by SFI-PGA or LFA-REALTM. Only LFA-REALTM reflected mild vs moderate/severe flares by BILAG (Table 2).

Table 1. Flares by mSFI and BILAG 2004.

mSFI flares

none

mild

moderate

severe

total

BILAG flares

none

321

32

0

0

353

mild

1

36

26

0

63

moderate

0

5

3

0

8

severe

0

0

5

1

6

total

322

73

34

1

430

Table 2. ROC analysis of changes in SFI-PGA and LFA-REALTM in differentiating mild from moderate/severe flares by mSFI and BILAG 2004.

mSFI

BILAG

Δ LFA-REALTM

AUC

0.7714

0.7466

p value

<0.0001

0.0041

Δ SFI-PGA

AUC

0.8348

0.6587

p value

<0.0001

0.0645

Conclusion: BILAG and mSFI flares are captured by changes in SFI-PGA or LFA-REALTM. BILAG flare thresholds are higher (mild flares require increase in 3 organs; moderate flares in a single organ default to mild). SFI compresses these into “mild-moderate”, which hinders clinically significant distinctions. The mSFI clinician’s discrimination of mild vs moderate/severe flare is supported by SFI-PGA or LFA-REALTM changes. LFA-REALTM can also distinguish mild vs moderate/severe BILAG flares, likely due to its expanded multisystem scale.

References: 1. Isenberg D, et al. Arthritis Care Res. 2018;70:98-103, 2. Thanou A, et al. Rheumatology 2014;53:2175-2181, 3. Petri M, et al. J Rheumatol.1992;19:53-9.


Disclosure: A. Thanou, None; A. Askanase, None; C. Arriens, AstraZeneca, 5; T. Aberle, None; S. Kamp, None; E. Chakravarty, None; J. A. James, None; J. T. Merrill, BMS, GSK, 2,BMS, GSK, UCB, Questcor, EMD Serono, Amgen, Celgene, Pfizer, RemeGen, Exagen, MedImmune, Lilly, Janssen, Xencor, Sanofi, Neovacs, Immupharma, Astellas, Glenmark, ILToo, 5,Have given talks for BMS but not for Speaker’s bureau, 9.

To cite this abstract in AMA style:

Thanou A, Askanase A, Arriens C, Aberle T, Kamp S, Chakravarty E, James JA, Merrill JT. Systemic Lupus Flares Based on BILAG and Sledai Rules Are Inconsistent, but May be Better Understood Using Visual Analogue Scales [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/systemic-lupus-flares-based-on-bilag-and-sledai-rules-are-inconsistent-but-may-be-better-understood-using-visual-analogue-scales/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systemic-lupus-flares-based-on-bilag-and-sledai-rules-are-inconsistent-but-may-be-better-understood-using-visual-analogue-scales/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology